http://www.frost.com/prod/servlet/svcg.pag/HCDD - Drug Discovery Technologies Research Mon, 12 May 2008 1:31:52 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D744-00-A1-00-00 This week's issue of Advanced Coatings and Surface Technology Alert focuses on innovative stent coating materials for better control and delivery of gene therapy, advances in suspension plasma sprayed titanium oxide coatings, description of surface topography with fractal and prolifometric methods, an affective approach to grow epitaxial graphene by using a carbon implant on silicon substrate, and synthesis of thin-multiwalled carbon nanotubes and characterization of field emission properties. Fri, 9 May 2008 23:41:37 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D950-00-0E-00-00 This week's issue of Drug Discovery Technology Alert profiles articles on a novel technology for drug formulation and oral drug delivery, a method to determine phosphorylation signatures, drugs that potentially prevent heart disease in kidney patients, vaccines to treat Alzheimer's Disease, a screenign tool with exceptional HTS and HCS capabilities, a novel anti-biofilm compound as an alternative to antibiotic therapy, MicroRNA antagonists as promising agents for Hepatitis C treatment and novel small molecules drugs capable of hindering the Aurora/Centrosome cancer pathway. Fri, 9 May 2008 23:41:37 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D813-00-61-00-00 This week's issue of Nutrition Alert profiles articles on recent findings pertaining to diets, soy protein, whey protein, MCTs, artificial sweetener, dietary fiber, fat soluble vitamins, mineral sources, foods affecting cholesterol and glucose levels, specialized formulas and supplements, weight loss therapy, and obesity. Fri, 9 May 2008 23:35:38 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D764-00-9A-00-00 This week's issue of Industrial Bioprocessing Alert profiles the development of starch-based biosustainable plastics; a polymer-based technology platform aiding in effective delivery of therapeutics and vaccines; ready made mini chromatography columns, which enable multiplexing of protein seperation; research findings enabling the removal of free fatty acids using zeolite catalysts; and finally analyst insights figuring out the strengths and success factors behind biofuels. Key patents from the bioprocess industry are also included. Fri, 9 May 2008 01:02:40 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D754-00-9B-00-00 This week's issue of GTN Alerts profiles the novel discovery of a gene, which can reverse angiogenesis and thus fight cancer; research findings aimed at retinal degeneration; dendrimers nanotechnology-based platform targeting treatment for life-threatening diseases; research findings highlighting gene therapeutic approach for spinal muscular atrophy; microRNAs emerging as lung cancer therapeutics; breakthrough studies generating cancer stem cells from embryonic stem cells source. This alert also highlights few prominent strategic partnerships and includes a coverage on key patents. Fri, 9 May 2008 00:57:38 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D754-00-9A-00-00 This week's issue of GTN Alert profiles articles on usage of zebrafish models for identification of potential drug candidates; promising gene therapy involving research findings, which could be eventually translated into addiction therapies; research findings highlighting the fact that vectors could deliver successful treatments; university studies focused on creating synthetic cells; nanotech-based system for genetic analysis; technology platform offering unique means of DNA isolation as well as effective means of detecting gene variations; and analyst perspectives on speculation surrounding the requirement of HPV vaccine mandate. The alert also delivers a snapshot of strategic partnerships and key patents. Fri, 2 May 2008 05:25:22 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D833-00-88-00-00 The current issue of Future Tech alert provides information on recent developments and futuristic overview of smart polymers used for biomedical applications that may impact the healthcare industry. It also analyzes the key innovations, trends, and relevant patents in this arena. Fri, 2 May 2008 03:18:22 +0100 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=128837508 Patient adherence is a continuing concern for the medical community and the drug industry. The following presentation is from the 3rd Annual Frost & Sullivan Executive Congress Committing to the Patient: Personalized Interventions that Drive Improved Adherence. Discussed are points including barriers to adherence, how these can be addressed, strategies to increase the flow of information, best practices in adherence programs, and solutions for improved adherence. Thu, 1 May 2008 00:00:00 +0100 http://www.frost.com/prod/servlet/report-homepage.pag?Src=RSS&repid=R2DE-01-00-00-00 Frost & Sullivan Awards are presented to companies that have exhibited excellence within their industry. This deliverable presents the Frost & Sullivan Awards for the U.S. Smoking Cessation Drug Market (N2DE-52). Mon, 28 Apr 2008 11:21:28 +0100 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=128762456 East African Infectious Diseases Diagnostics Market Mon, 28 Apr 2008 00:00:00 +0100 http://www.frost.com/prod/servlet/report-homepage.pag?Src=RSS&repid=R30B-01-00-00-00 Frost & Sullivan Awards are presented to companies that have exhibited excellence within their industry. This deliverable presents the Frost & Sullivan Awards for the U.S. Alcohol Dependence and Abuse Pharmaceuticals Market - Therapeutic Overview and Patient Outlook (N30B-52). Fri, 25 Apr 2008 10:31:34 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D850-00-6E-00-00 This week's edition of Medical Device Technology Alert features articles on a clinical system for anaesthesia, a ventricular assist device, an implantable device for tracking tumors and fising radiation dose, a peripheral artery bypass graft, inner ear implant, bioartificial pancreas, a nanotech-based device for drug delivery, and nanotube sensors to monitor insulin levels. Fri, 25 Apr 2008 04:49:35 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D754-00-98-00-00 This week's issue of GTN Alert profiles articles on a technology platform employing genetic chemistry for cost-effective drug development, spinal muscular atrophy treatment enabled through targeted gene alteration method, RNAi technology utilized for the production of human therapeutic glycoproteins, biomarkers for assessment of cancer therapy outcome, a novel gene sequencing technique enabling researchers to obtain sequence information from single molecules of DNA devoid of gene amplification, novel gene shuffling technique for production of optimized proteins, and an innovative magnetic targeting approach to effectively target tumors.The alert also provides insights into important strategic partnerships as well as important patents. Fri, 25 Apr 2008 04:39:34 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D764-00-98-00-00 This week's alert features the world's first commercially viable cellulosic ethanol plant and a plant system for high-quality human collagen production. In addition, protein engineering technologies for production of functionally optimized biotherapeutics, and some important patents have been featured. Fri, 25 Apr 2008 04:39:34 +0100 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=128459886 European Mass Spectrometry Market Wed, 23 Apr 2008 00:00:00 +0100 http://www.frost.com/prod/servlet/report-homepage.pag?Src=RSS&repid=M1C3-01-00-00-00 This research service provides a strategic outlook of the pharma/Biotech contract manufacturing markets in Europe. It includes technology trends, challenges, drivers, restraints, competitive structure, strategic recommendations and list of market participants. Tue, 22 Apr 2008 07:02:39 +0100 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=128394740 Declining productivity and thinning R&D pipeline despite high R&D intensity is probably the most oft repeated phrase used to characterise the current research based pharmaceutical industry. Tue, 22 Apr 2008 00:00:00 +0100 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=128139041 Adapt and Defend: Strategies to Sustain the ELISA Market in Face of Multiplex Shift Sat, 19 Apr 2008 00:00:00 +0100 http://www.frost.com/prod/servlet/report-homepage.pag?Src=RSS&repid=N36A-01-00-00-00 This research service provides an in-depth analysis of the U.S. clinical trial management systems market. The research service includes revenue forecasts, data management needs analysis, vendor analysis, market drivers and challenges. Fri, 18 Apr 2008 15:44:35 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D950-00-0D-00-00 This week's issue of Drug Discovery Technology Alert profiles articles on isobaric mass tags that enhance accuracy and reproducibility of proteomic experiments, a unique method of cell-free gene expression, microfluidic chip-based technology for cell-based assys for drug discovery, a virtual method of drug screening for drug discovery, aptamer-based biomarker discovery technique, a novel screening technique that enhances fragment-based drug discovery, microfluidic technology to study platelet aggregation, and combination therapy for prostrate cancer. Fri, 18 Apr 2008 06:44:40 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D754-00-97-00-00 This week's issue of GTN Alert profiles articles on novel therapeutic potential of epigenetic targets, a chemically linked immunogenic peptides on scaffolds technology platform for generating functional antibodies,findings of bacteria that consume both natural as well as synthetic antibiotic compounds, promising therapeutic targets for GERD disease utilizing allosteric modulation mechanism, research findings highlighting mother precursor cells to dopaminergic neurons found in early brain development stages, study findings indicating that molecular changes in the brain are clearly reflected by presence of biomarkers, easy to administer single dose typhoid vaccine and data analysis software for pyrosequencing of DNA. Fri, 18 Apr 2008 04:45:41 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D860-00-2E-00-00 This week's edition of Medical Diagnostic Imaging Technology features articles that include quantification of mitral regurgitation,graphical user interface for intelligent analysis, detection of frost bite in biological tissues, an image analysis technology that facilitates better diagnosis, a novel cancer detection device, a non-invasive technique to assess bone strength and quality, a device that tackles the shortcomings of fluorescent imaging, a mechanical imaging system for diagnosing prostate cancer and a device that is positioned as an effective substitution for the painful processes involved in cervical examination Fri, 18 Apr 2008 04:39:41 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D784-00-99-00-00 Fuzzy-Logic Delivery Systems--Functionalized solid lipid nanoparticles with complex surface chemistry are a big step in creating smart imaging and therapeutic agents for treatments for cancers. Semitransparent conductive coatings with tunable optical transmittance can be produced using metallic SWNTs. A new technique creates nanodroplet test tube' for studying individual proteins. A nanomotor uses a thermal gradient to move and rotate cargo from one end of a CNT to the other. EU project will look fostering dialogue on nanotech opportunities and risks in Europe. Fri, 18 Apr 2008 04:33:41 +0100 http://www.frost.com/prod/servlet/report-homepage.pag?Src=RSS&repid=N369-01-00-00-00 The U.S. Non-Infectious Disease Vaccine Pipeline research service contains an overview of the vaccine pipeline and development information for non-infectious diseases (Oncology, Cardiovascular, Multiple Sclerosis, Addiction Disorders). The research service also provides an overview of vaccine development, major challenges, and conclusions. Fri, 11 Apr 2008 10:38:22 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D850-00-6D-00-00 This week's edition of Medical Device Technology Alert features articles on treatment of motor diseases, epileptic seizure alarm, microfluidic chip based on femtosecond lasers, a prescreening tool for sleep apnea, cardiac surgery performed using robots, automatic wheelchairs using EMG signals, mitral valve stimulators, and a bioabsorbable plaque for effective closure of arterial puncture. Fri, 11 Apr 2008 05:57:22 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D813-00-60-00-00 Fri, 11 Apr 2008 05:52:22 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D754-00-96-00-00 This week's issue of Genetic Technology Alert profiles articles on a technology platform for DNA methylation, herbal dietary supplement to aid in neurological functions, quantification of amyloid beta peptides, molecular mechanism against tuberculosis bacterium, altered polyketides, short hairpin RNAs, a novel recombinant protein production technology, and discovery of viral gene that causes obesity. The alert also provides important patents. Fri, 11 Apr 2008 05:42:24 +0100 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=127102083 According to a study conducted by New York University researchers, U.S. Pharmaceutical Companies are spending almost twice as much on advertising as on research and development. This study called The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States was published in the January 3, 2008 issue of PLoS Medicine. It analyzed data collected from two sources and concluded that the U.S. pharmaceutical industry spent 24.4 percent of the money earned in sales on promotion and only 13.4 percent for research and development. This study authored by PhD candidate Marc-Andre Gagnon and Dr. Joel Lexchin, examined data collected from 2004 reports from IMS Health and CAM Group. From these, they were able to get sales and marketing data for the pharmaceutical industry. It was noted by the authors that the numbers from IMS Health and CAM Group did not agree. This was attributed to the different sources of information for both sources as IMS Health gets its information directly from the Pharmaceutical companies while CAM Group gets their information from doctors. According to CAM Group, $33.5 billion was spent by the pharmaceutical industry for total promotion spending compared to the $27.7 billion reported by IMS Health. The authors combined select information obtained from both sources and deduced that the total promotion spending in 2004 was $57.5 billion. Tue, 8 Apr 2008 00:00:00 +0100 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=127102252 On March 13, 2008, a new bill was introduced into the House that would create a way for the FDA approval of biogenerics. H.R. 5629 is a bipartisan bill called the Pathways for Biosimilars Act. This bill was introduced by Representatives Anna Eshoo (Democrat, California) and Joe Barton (Republican, Texas). This bill provides a way for biosimilars to be approved by referencing an approved biological product. As part of the application process, the applicant must submit results from studies that show that their biological product is in fact highly similar to the referenced approved product. Not only does this bill offer a pathway for the approval of biosimilars, but it also provides for 12 years of exclusivity to the first product licensed (reference product). In addition, this exclusivity can be extended to two years for medically significant new indications and for an additional six months for approvals in the pediatric population. For conventional medications there are standards in place for the approval of generic compounds, mainly the Hatch-Waxman act. However for biologics there are no set regulatory standards. In addition, biologics are approved following the filing of a Biologics Licensing Application (BLA) as opposed to a New Drugs Application (NDA). This puts monoclonal antibodies under the Public Health Services Act which makes them ineligible for approval under the Hatch-Waxman act. Tue, 8 Apr 2008 00:00:00 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D754-00-95-00-00 This week's issue of Genetic Technology Alert profiles articles on a novel tool for immediate visualization of proteins during the course of protein production in Escherichia coli and protein purification, a novel class of anticancer drugs that primarily disrupt tumor vasculature, angiogenic cell precursor-based technology platform for heart disease treatment, resistance mechanism of Methicillin-resistant Staphylococcus aureus (MRSA) to natural defenses, a breakthrough technology for DNA engineering, discovery of gene behing amyotropic lateral sclerosis (ALS), study that reveals the role of rare gene mutatiosn in schizophrenia and mutated HIV vaccine strategy. The alert also covers important patents and strategic partners. Fri, 4 Apr 2008 03:08:23 +0100 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=126368892 The global economic canvas is currently faced with several challenges Wed, 2 Apr 2008 00:00:00 +0100 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=126405293 Drug Delivery - Assessing Market and End User Opportunities for Product Design Wed, 2 Apr 2008 00:00:00 +0100 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=126245706 Strategic Outlook of the European Pharma/Biotech Contract Manufacturing Markets Tue, 1 Apr 2008 00:00:00 +0100 http://www.frost.com/prod/servlet/report-homepage.pag?Src=RSS&repid=D0FD-01-00-00-00 This research service provides the latest trends in apoptosis research and future developments Mon, 31 Mar 2008 01:24:23 +0100 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=126134255 Stem cells can be considered the basis for every organ, tissue and cell within the human body, and are classified into two distinct types: adult stem cells and embryonic stem cells. While the first ones are derived from developed organs or tissues, such as the bone marrow or the cord blood of newborns' umbilical cords, the second ones are obtained from embryos resulted by in vitro fertilization. Mon, 31 Mar 2008 00:00:00 +0100 http://www.frost.com/prod/servlet/report-homepage.pag?Src=RSS&repid=D103-01-00-00-00 This research service analyses the latest developments that has occurred in the field of theranostics, both from a technology and industry perspective. Sun, 30 Mar 2008 23:31:24 +0100 http://www.frost.com/prod/servlet/report-homepage.pag?Src=RSS&repid=D114-01-00-00-00 This research service outlines the key global developments in cardiovascular drug therapies. Sun, 30 Mar 2008 23:27:04 +0100 http://www.frost.com/prod/servlet/report-homepage.pag?Src=RSS&repid=D0FE-01-00-00-00 This research service analyzes the global trends in the metabolomics with a focus on the current and prospective applications of this platform. Sun, 30 Mar 2008 23:22:53 +0100 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D754-00-94-00-00 Genentech has chosen an inhibitor of MEK, a member of the MAP pathway, from Exelixis to further develop for treating cancer. Pending final analysis of completed animal toxicology studies NIH and Avicena are ready to start clinical testing of Avicena's lead product candidate, designed to slow the progress of Huntington's disease. VistaGen has formed an alliance with University Health Network to carry out research into advanced techniques to differentiate embryonic stem cells into mature cardiac, liver, and pancreatic beta-islet cells. Centocor and Schering Plough have applied to European regulatory authorities to market golimumab for treating three different autoimmune diseases. Fri, 28 Mar 2008 03:44:17 +0000 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=125783582 Statistical data suggest that today, there are about 150,000 new cancer cases detected in Mexico each year. In comparison with other developed regions such as in United States (U.S.) and the European Union (E.U.) , cancer incidence in Mexico does not seem to be a major concern for Health Authorities. However this does not reflect reality, as Mexico's cancer incidence rates are somehow distorted and do not reflect the dramatic increase of this disease in the Mexican population. Fri, 28 Mar 2008 00:00:00 +0000 http://www.frost.com/prod/servlet/report-homepage.pag?Src=RSS&repid=M20E-01-00-00-00 This research service give a detailed analysis of the European LIMS market from 2007 to 2014. The effect of various drivers and challenges for the LIMS market are discussed and revenue forecasts provided based on market dynamics. Customer requirements and technology trends are also discussed. The segmentation include LIMS application for pharmaceutical R&D, manufacturing and clinical trials data management. Strategic recommendations are provided for the various challenges facing LIMS vendors in the European market. Thu, 27 Mar 2008 05:16:17 +0000 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D754-00-93-00-00 Sitris has obtained rights to technology for introducing the NamPRT gene into aging human vascular smooth muscle cells to delay their deterioration. KaloBios is developing a monoclonal antibody against granular macrophage colony-stimulating factor (GM-CSF) to treat inflammation associated with asthma. Cardium's gene therapy prevents reperfusion injury in heart attack patients. Curis looking for a new partner for hedgehog pathway protein agonists for treating stroke after Wyeth discontinued its collaboration. AlphaMed has successfully expressed a glycosylated human version of alpha 1-antitrypsin (AAT) in yeast. Applied Biosystems has brought the cost of sequencing a complete human genome down to $60,000. Fri, 21 Mar 2008 22:37:18 +0000 http://www.frost.com/prod/servlet/report-homepage.pag?Src=RSS&repid=N133-01-00-00-00 This research service analyzes the market for cell-based assays within the United States. This market was divided into three segments, covering cell growth-associated assays, cell death-associated assays, and functional cell assays. Each segment of this service provides an overview, analysis of products available, revenue forecasts, and market share analysis. Key challenges and strategies are covered for the total market, as are market drivers and restraints. This study presents information on key research and drug discovery applications expected to influence the market, and highlights recent developments and product features that should be emulated by market participants to achieve corporate growth objectives. Fri, 21 Mar 2008 09:06:17 +0000 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=124965013 The pharmaceutical industry is in an era when it has reached the crossroads, facing multiple challenges. The industry is plagued by the need to reduce timescales for new drug discovery, shrinking profit margins, supply chain pressures and changing regulatory requirements, while more and more drugs go off-patent. Amidst all these issues pharmaceutical companies need to sustain valuable growth in highly competitive markets and these challenges have clearly not de-motivated them from launching new products in the market. Thu, 20 Mar 2008 00:00:00 +0000 http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=124736055 The current estimates place the cost to develop a drug from concept to market at more than $800 million with a rise to as much as $1.7 billion when taking into account pre-launch marketing costs, with a total time period of up to 15 years. The speed at which drug development is expected to bring novel drug targets to the market is challenging not only for small start-up companies but also for large, well-established firms. Issues like unavailability of analytical methods, reagents, relevant animal models, experienced staff and adequate funding, quality of data, regulatory pathway and the management team are all factors contributing to the delay of novel therapies. Tue, 18 Mar 2008 00:00:00 +0000 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D950-00-0C-00-00 This week's edition of the Drug Discovery Technology Alert features articles on promising class of anticancer compunds, transdermal microprojection patch for drug delivery, adult stem cell therapies for bone, joint, and cardiovascular diseases, novel small molecule drug for cancer, plant-based protein expression system, protein therapeutic for wound healing, mitochondrial analysis tool kits for studying drug effects and siRNA therapies for ovarian cancer. Fri, 14 Mar 2008 04:56:38 +0000 http://www.frost.com/prod/servlet/market-service-segment.pag?Src=RSS&segid=D754-00-92-00-00 GammaCan's therapy using immunoglobulins from donors with vitilgo, a skin disorder, shows promise against melanoma in animal experiments. Biovitrum and Syntonix advance clinical testing of a long-acting recombinant factor IX to treat hemophilia B patients. Zevalin, a monoclonal antibody linked to a cell-killing radioactive isotope, combined with CHOP chemotherapy attains a 100% response rate in elderly patients with diffuse large B-cell lymphoma. Research at Dendreon validates the marker it has been using to measure the potency of its Provenge individualized cell therapy before administering it for prostate cancer treatment. Amgen licenses a monoclonal antibody with potential for treating inflammatory disorders and cancer from Kyowa Hakko. Fri, 14 Mar 2008 03:44:39 +0000